CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale.
CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide.
The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership.
Strategic Partnerships Powering the Summit
CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi government partners shaping the Kingdom's mobility future: Royal Commission for Riyadh City (RCRC), Riyadh Municipality, Ministry of Transport & Logistic Services (MoTLS), Riyadh Public Transport, Ministry of Municipalities and Housing (MoMH), Ministry of Communications and Information Technology (MCIT), Digital Government Authority (DGA), and Transport General Authority (TGA).
The event features keynote addresses from H.E. Fahd bin Abdulmohsan Al Rasheed, Chairman of SCEGA and Head of the Saudi Arabian Delegation to the Urban 20, and H.E. Dr. Rumaih Al Rumaih, Vice Minister of Transport & Logistic Services and Acting President of TGA and private sector leaders like Mate Rimac of Croatia’s Rimac Automobili; Bill Russo, Founder & CEO, Automobility Ltd.; Dr. James Yu, Chairman and CEO, QCraft; Chris Li, Co-founder and CFO, Neolix; Jinjun Tian, CEO, Geely Auto Middle East; Valerie Labi, CEO & Co-Founder, Wahu Mobility; and Yvonne Aki-Sawyerr, Mayor, Freetown, South Africa and Chair, C40.
Leading private-sector mobility partners – Uber, door2door, Budget Saudi Arabia, and Changan Almajdouie – are supporting the event with advanced transport services and EV solutions, demonstrating the Kingdom's accelerating shift toward cleaner, more connected mobility systems.
Climate Leadership Through The Bridge Initiative
CoMotion GLOBAL 2025 is fully climate-offset through The Bridge Initiative, which supports high-integrity climate action across the Global South. The initiative measures event emissions, selects high-quality carbon credits, and retires them to certify the summit's climate contribution.
For this year's event, The Bridge Initiative selected a major waste-to-energy project in Bogotá, Colombia, that captures methane from one of Latin America's largest landfills and converts it into renewable electricity and biomethane. The project reduces roughly 800,000 tons of CO₂e annually – equivalent to removing 400,000 cars from the road. Certified by CerCarbono, it delivers environmental impact and social benefits, improving air quality for nearby low-income communities while ensuring transparency in climate action.
A Dynamic Agenda Shaping Mobility's Future
CoMotion GLOBAL 2025 features a two-stage program, dedicated Mobility Labs, the inaugural CoMotion Urban Visionary Distinction, and the launch of Mayors in Motion – a global network for city leaders to exchange insights, coordinate strategies, and champion practical solutions.
Key themes include the Kingdom's emergence as a first-wave deployment market for autonomous technologies, exclusive insights into Riyadh's groundbreaking 176-km metro megaproject, and the rapid growth of EV manufacturing, adoption, and infrastructure. The summit will also explore how Expo 2030 and the 2034 World Cup can drive long-term mobility upgrades.
Global spotlights will highlight Africa's shared-mobility breakthroughs, Latin America's electrification leadership, China's mobility playbook, and AI-driven logistics advances from North America and Europe, and the advent of Sentient Cities in the Middle East and internationally.
"CoMotion GLOBAL is where the world's urban mobility future takes shape, and the energy in Riyadh today is extraordinary," said John Rossant, Founder and CEO of CoMotion GLOBAL. "From ministers to mayors to the world's most inventive technologists, the conversation is clear: the next decade of mobility transformation will be shaped at the city level. Riyadh is the perfect host for that dialogue – bold, ambitious, and redefining what a future-ready city can be."
About CoMotion
CoMotion is the world’s leading platform where the most influential leaders, companies, startups, and policymakers meet to shape the future of mobility. With flagship events in Riyadh, Los Angeles, and Miami, CoMotion fosters meaningful dialogue and catalyzes investments that advance sustainable and equitable transportation worldwide.
For more information, visit www.comotionglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251207218971/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom